>>188918, >>188919, >>188920, >>188921, >>188922, >>188923, >>188924, >>188925, >>188926, >>188927, >>188928, >>188929, >>188930, >>188931, >>188932, >>188933, >>188934, >>188935, >>188936, >>188937, >>188938, >>188939, >>188940, >>188941, >>188942, >>188943, >>188944, >>188945, >>188946, >>188948, >>188949, >>188951, >>188953, >>188954, >>188955, >>188956, >>188957, >>188958, >>188959, >>188960, >>188961, >>188962, >>188963, >>188964, >>188965, >>188966, >>188967, >>188968, >>188969, >>188970, >>188971, >>188972, >>188973, >>188974, >>188975, >>188976, >>188977, >>188978, >>188979, >>188980, >>188981, >>188982, >>188983, >>188984, >>188985, >>188986, >>188987, >>188988, >>188989, >>188990, >>188991, >>188992, >>188993, >>188994, >>188995, >>188996, >>188997, >>188998, >>188999, >>189000, >>189001, >>189002, >>189003, >>189004, >>189005, >>189006, >>189007, >>189008, >>189009, >>189010, >>189011, >>189012, >>189013, >>189014, >>189015, >>189016, >>189017, >>189018, >>189019, >>189020, >>189021, >>189022, >>189023, >>189024, >>189025, >>189026, >>189027, >>189028, >>189029, >>189030, >>189031, >>189032, >>189033, >>189034, >>189035, >>189036, >>189037
The results presented in this study demonstrate the potential of methylene blue (MB) metabolic therapy as an effective treatment approach for ovarian cancer
“stronger reduction in proliferation observed in TOV112D (platinum resistant cancer) cells compared to ARPE-19 (normal ovarian) cells in response to the MB-50 treatment highlights the potential of methylene blue as a therapeutic agent that specifically targets ovarian cancer cells”
"addition of carboplatin to MB-50 exhibited a slight impact on the TOV112D proliferation compared to MB-50 alone, suggesting a potential additive effect of carboplatin in combination with methylene blue, albeit to a limited extent."
modest enhancement of the in vivo tumor response observed to the combination of MB and carboplatin (MB + carboplatin) raises the possibility of a synergistic effect between methylene blue and carboplatin
“it would be highly relevant to identify the metabolic pathways as well as the signaling pathways involved in the inhibition of cancer cell growth by methylene blue”
“In conclusion, this study provides crucial insights into the potential of methylene blue-guided metabolic therapy for treating ovarian cancer. The results underscore the promise of metabolic therapy in reducing tumor growth by addressing the mitochondria redox potential, akin to its role as an oxidative agent in bacterial diseases. However, there is a pressing need for further investigations into the specific impact of methylene blue on apoptotic signaling and metabolic pathways within cancer cells. These molecular mechanisms must be thoroughly elucidated to optimize the application of metabolic therapy and enhance the treatment outcomes, particularly in the context of chemoresistant ovarian cancers.
My Take…
I will be writing a series of articles on Methylene Blue and Cancer over the coming days.
In this paper, methylene blue had a dramatic effect on ovarian cancer cell proliferation, oxygen consumption rate in tumor cells and on tumor growth.
However, the pathways are unknown.
Interestingly, while MB slowed the tumor growth rate significantly (much better than chemo), it didn’t stop the tumor growth.
The authors admit they don’t really know exactly how methylene blue works against ovarian cancer.
Over the coming days and weeks, I will try to determine how Methylene Blue can be used in cancer and what the appropriate dosing would be.
Article Link in photo to avoid shadowban, just re-type the URL in the first photo at the top, into your browser to access.
@JoeRogan
https://x.com/MakisMedicine/status/1888181895130698088